Highlights and Quick Summary
- Annual Depreciation/Fixed assets for 2019 was 1.18 (a 388.68% increase from previous year)
- Annual Depreciation/Fixed assets for 2018 was 0.24 (a 16.08% increase from previous year)
- Twelve month Depreciation/Fixed assets ending June 29, 2020 was 1.09 (a 0.59% increase compared to previous quarter)
- Twelve month trailing Depreciation/Fixed assets increased by 17.14% year-over-year
Trailing Depreciation/Fixed assets for the last four month:
|29 Jun '20||30 Mar '20||30 Dec '19||29 Sep '19|
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Depreciation/Fixed assets of Entera Bio Ltd.Most recent Depreciation/Fixed assetsof ENTX including historical data for past 10 years.
Interactive Chart of Depreciation/Fixed assets of Entera Bio Ltd.
Entera Bio Ltd. Depreciation/Fixed assets for the past 10 Years (both Annual and Quarterly)
Business Profile of Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.